OTCM
OTSKY
Market cap38bUSD
Oct 08, Last price
36.92USD
1D
2.03%
1Q
5.34%
Jan 2017
68.43%
IPO
24.02%
Name
Otsuka Holdings Co Ltd
Chart & performance
P/E
16.87
P/S
2.48
EPS
691.20
Div yield, %
1.26%
Shrs. gr., 5y
-0.45%
Rev. gr., 5y
11.65%
Revenues
2.47t
+5.97%
Net income
363.15b
+5.84%
CFO
403.58b
+13.80%
Dividend
Dec 29, 20260.32103 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded on July 8, 2008 and is headquartered in Tokyo, Japan.
Key people
Ichiro Otsuka
Chairman of the Board, Representative Director · since 2022
Makoto Inoue
President, Chief Executive Officer, President of Subsidiary, Representative Director · since 2025
Yuko Makino
Chief Financial Officer, Director · since 2019
Tatsuo Higuchi
Chairman of Subsidiary, Director · since 2025
Shuichi Takagi
President of Subsidiary, Director · since 2024
Noriko Tojo
President of Subsidiary, Director · since 2020
Yoshiro Matsuo
Vice President, Representative Director · since 2025
Chiaki Sakurai
Senior Managing Executive Officer, Chief Director of Nutraceuticals Business Global Strategy and Planning · since 2025
Tomohiro Emura
Managing Executive Officer · since 2025
Manabu Kawata
Managing Executive Officer · since 2022
Keiso Yamasaki
Managing Executive Officer, Director of Business Planning · since 2024
Hiroki Nakayama
Executive Officer, Director of Internal Audit · since 2022
Aki Sudo
Executive Officer, Director of Internal Control · since 2022
Masanori Udagawa
Executive Officer, Director of IT Planning · since 2022
Masayuki Kobayashi
Chairman & President of Subsidiaries, Director · since 2017
Yoshihisa Aoki
Independent Director · since 2019
Tatsuaki Kitachi
Independent Director · since 2022
Yukio Matsutani
Independent Director · since 2016
Mayo Mita
Independent Director · since 2020
Jiro Seguchi
Independent Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||